Literature DB >> 23780926

Novel and simple prognostic index for nasal natural killer/T-cell lymphoma.

Hiroyuki Hanakawa1, Yorihisa Orita, Yasuharu Sato, Soshi Takao, Hidenori Marunaka, Tokiwa Morishita, Yasuhiko Yamashita, Yasutaka Hori, Shuhei Domae, Ikuo Inokuchi, Seiko Akagi, Eisei Kondo, Noriko Iwaki, Kana Motomiya, Hirokazu Okumura, Tadashi Yoshino, Kazunori Nishizaki.   

Abstract

BACKGROUND: Few studies have investigated the prognostic factors for nasal natural killer (NK)/T-cell lymphoma.
METHODS: This was a retrospective multicenter clinical study. The clinical records of 36 patients with nasal NK/T-cell lymphoma who had been first treated between 1996 and 2011 were collected from 12 hospitals.
RESULTS: High serum levels of C-reactive protein (≥1.0 mg/dL), lactate dehydrogenase (≥350 IU/L), and soluble interleukin-2 receptor (sIL-2R; ≥600 U/mL) were associated with worse prognosis. A prognostic score was devised by totaling the number of these 3 predictors: 0 or 1 = score 0; and 2 or 3 = score 1. As for tumor invasion, local invasion beyond the nasal cavity was associated with poor prognosis, and a prognostic score was devised as: tumor restricted to nasal cavity, yes = score 0; no = score 1. A novel prognostic index (NPI) was established based on these scores from 0 to 2. Disease-specific survival rates at 5 years were: 90.0% for NPI = 0; 29.3% for NPI = 1; and 0.0% for NPI = 2.
CONCLUSION: Our NPI is valid for anticipating prognosis of nasal NK/T-cell lymphoma.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  blood examination; local invasion; nasal NK/T-cell lymphoma; prognosis; prognostic index

Mesh:

Substances:

Year:  2013        PMID: 23780926     DOI: 10.1002/hed.23322

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.

Authors:  Y Q Wang; Y Yang; H Y Zhuo; L Q Zou; Y Jiang; M Jiang
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

Review 2.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Authors:  Bradley M Haverkos; Zenggang Pan; Alejandro A Gru; Aharon G Freud; Rachel Rabinovitch; Meng Xu-Welliver; Brad Otto; Carlos Barrionuevo; Robert A Baiocchi; Rosemary Rochford; Pierluigi Porcu
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

3.  The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma.

Authors:  Xi-Wen Bi; Liang Wang; Wen-Wen Zhang; Shu-Mei Yan; Peng Sun; Yi Xia; Zhi-Ming Li; Wen-Qi Jiang
Journal:  PeerJ       Date:  2016-03-03       Impact factor: 2.984

4.  Correlation between the clinicopathological features and prognosis in patients with extranodal natural killer/T cell lymphoma.

Authors:  Lin-Shu Zeng; Wen-Ting Huang; Tian Qiu; Ling Shan; Lei Guo; Jian-Ming Ying; Ning Lyu; Xiao-Li Feng
Journal:  Chronic Dis Transl Med       Date:  2017-12-13

5.  High C-Reactive Protein to Albumin Ratio Predicts Inferior Clinical Outcomes in Extranodal Natural Killer T-Cell Lymphoma.

Authors:  Quan-Shu Di; Tao Xu; Ying Song; Zhi-Gang Zuo; Feng-Jun Cao; Xiong-Jie Yu; Ji-Ying Tang; Wei Zhang; Chen Li; Guo-Xing Wan; Xiao-Jun Cai
Journal:  Dose Response       Date:  2020-04-07       Impact factor: 2.658

6.  Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma.

Authors:  Changqian Bao; Lixia Zhu; Wenbin Qian; Xiujin Ye
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.